2. Signaling Pathways
  3. GPCR/G Protein
  4. Bradykinin Receptor
  5. Bradykinin Receptor Antagonist

Bradykinin Receptor Antagonist

Bradykinin Receptor Isoform Comparison

Bradykinin Receptor Antagonists (21):

Cat. No. Product Name Effect Purity
  • HY-17446
    Icatibant
    		Antagonist 99.51%
    Icatibant (HOE-140) is a potent and specific peptide antagonist of bradykinin B2 receptor with IC50 and Ki of 1.07 nM and 0.798 nM respectively.
  • HY-108896
    Icatibant acetate
    		Antagonist 99.65%
    Icatibant acetate (HOE-140 acetate) is a potent and specific peptide antagonist of bradykinin B2 receptor with an IC50 and Ki of 1.07 nM and 0.798 nM respectively.
  • HY-15039
    SSR240612
    		Antagonist 99.51%
    SSR240612 is a potent, and orally active specific non-peptide bradykinin B1 receptor antagonist, with Kis of 0.48 nM and 0.73 nM for B1 kinin receptors of human fibroblast MRC5 and HEK cells expressing human B1 receptors, 481 nM and 358 nM for B2 receptors of guinea pig ileum membranes and CHO cells expressing human B1 receptor, respectively.
  • HY-17446R
    Icatibant (Standard)
    		Antagonist
    Icatibant (Standard) is the analytical standard of Icatibant. This product is intended for research and analytical applications. Icatibant (HOE-140) is a potent and specific peptide antagonist of bradykinin B2 receptor with IC50 and Ki of 1.07 nM and 0.798 nM respectively.
  • HY-147273
    Fulimetibant
    		Antagonist 99.74%
    Fulimetibant is a bradykinin receptor antagonist.
  • HY-103289
    MEN 11270
    		Antagonist 99.15%
    MEN 11270, a cyclic decapeptide, is a B2 kinin receptor antagonist. MEN 11270 bound with high-affinity to the B2 kinin receptor constitutively expressed by WI38 human fibroblasts, inhibiting 3H-bradykinin (BK) with a pKi value of 10.3.
  • HY-15043
    ELN-441958
    		Antagonist 99.51%
    ELN-441958 is a potent, neutral, competitive and selective bradykinin B1 receptor antagonist with a Ki of 0.26 nM against native human bradykinin B1 receptor. ELN-441958 has high oral bioavailability, and has low CNS exposure in the mouse.
  • HY-103290
    R715
    		Antagonist 99.45%
    R715 is a selective bradykinin B1 receptor antagonist. R715 significantly attenuates the hyperalgesic effect developed in Streptozotocin(HY-13753)-diabetic mice.
  • HY-P4676
    Lys-(Des-Arg9,Leu8)-Bradykinin
    		Antagonist 98.23%
    Lys-(Des-Arg9,Leu8)-Bradykinin is a bradykinin B1 receptor antagonist.
  • HY-106277
    Fasitibant free base
    		Antagonist
    Fasitibant (free base) is a potent, selective, high affinity, and long-lasting nonpeptide bradykinin B2 (BK2) receptor antagonist. Fasitibant (free base) has proinflammatory effects and can be used for the research of osteoarthritis and rheumatoid arthritis.
  • HY-P3232
    B 9430
    		Antagonist
    B 9430 is a potent bradykinin B1/B2 receptor antagonist.
  • HY-106277A
    Fasitibant chloride hydrochloride
    		Antagonist
    Fasitibant chloride hydrochloride (MEN16132) is a potent, selective, high affinity, and long-lasting nonpeptide bradykinin B2 (BK2) receptor antagonist. Fasitibant chloride hydrochloride has proinflammatory effects and can be used for the research of osteoarthritis and rheumatoid arthritis.
  • HY-100301
    FR167344 free base
    		Antagonist
    FR167344 free base is an orally active, nonpeptide bradykinin receptor B2 antagonist. FR167344 free base shows a high affinity binding to the B2 receptor with an IC50 value of 65 nM and no binding affinity for the B1 receptor.
  • HY-121156
    LF 16-0687
    		Antagonist
    LF 16-0687 (XY-2405) is a selective non-peptide bradykinin B2 receptor antagonist. LF 16-0687 binds to the human, rat and guinea-pig recombinant B2 receptor with Ki values of 0.67 nM, 1.74 nM and 1.37 nM, respectively. LF 16-0687 crosses the blood-brain barrier (BBB). LF 16-0687 can be used in research on brain damage diseases.
  • HY-158262
    Bradykinin B1 receptor antagonist 1
    		Antagonist
    Bradykinin B1 receptor antagonist 1 (compound 6B) is a potent and cross the blood-brain barrier bradykinin B1 antagonist. Bradykinin B1 receptor antagonist 1 has the potential for the research of pain.
  • HY-100827
    Safotibant
    		Antagonist
    Safotibant (LF22-0542) is a selective antagonist for kinin B1 receptor (BKB1R), with Ki of 0.35 and 6.5 nM, for human and mouse BKB1R, respectively. Safotibant exhibits analgesic and anti-inflammatory property in mice model.
  • HY-14886
    Fasitibant chloride
    		Antagonist
    Fasitibant chloride (MEN16132 free base) is a potent and selective nonpeptide bradykinin B2 receptor (B2R) antagonist. Fasitibant chloride reduces joint pain and diminishes joint oedema in Carrageenan-induced arthritis rat model.
  • HY-15791
    FR173657
    		Antagonist
    FR173657 is an orally active bradykinin B2 receptor antagonist (IC50: 0.56, 1.5, 2.9 nM for pig, rat, human B2 receptor respectively). FR173657 (p.o.) inhibits BK-induced bronchoconstriction in guinea-pigs (ED50: 0.075 mg/kg). FR173657 (p.o.) also inhibits Carrageenin-induced paw oedema in mice (ED50: 6.8 mg/kg). FR173657 can be used for research of inflammatory disease.
  • HY-P2118
    NPC-567
    		Antagonist
    NPC-567 is a bradykinin B2 receptor antagonist. NPC-567 is effective in inhibiting the acute response to allergen in the airways.
  • HY-101368A
    WIN 64338 hydrochloride
    		Antagonist
    WIN 64338 hydrochloride is a potent, selective, nonpeptide competitive antagonist of bradykinin B2 receptor. WIN 64338 hydrochloride inhibits [3H]-Bradykinin binding to the bradykinin B2 receptor on human IMR-90 cells with a Ki of 64 nM. WIN 64338 hydrochloride also can inhibits [3H]Quinuclidinyl benzilate binding to the rat brain muscarinic receptor (Ki=350 nM).